December 10, 2018
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
FDA approves Alembic’s allergic conjunctivitis treatment
The FDA has approved an abbreviated new drug application for olopatadine hydrochloride ophthalmic solution 0.1%, Alembic Pharmaceuticals announced in a press release.
The solution is therapeutically equivalent to Patanol ophthalmic solution 0.1% (Novartis), the release said.
It is indicated for the treatment of signs and symptoms of allergic conjunctivitis.